Contraindicated in:
- Hypersensitivity;
- History of angioedema with or without previous use of ACE inhibitors;
- Concurrent use with aliskiren in patients with diabetes or moderate to severe renal impairment (CCr <60 mL/min);
- OB: Pregnancy.
Use Cautiously in:
- Renal impairment, hypovolemia, hyponatremia, and concurrent use of diuretics;
- Black patients (monotherapy for hypertension less effective; may require additional therapy; higher risk of angioedema);
- Surgery/anesthesia (hypotension may be exaggerated);
- Lactation: Use while breastfeeding only if potential maternal benefit outweighs potential risk to infant;
- Pedi: Children <6 yr (safety not established);
- Geri: Initial dose ↓ recommended in older adults.
Exercise Extreme Caution in:
- Family history of angioedema.
Therapeutic Classification: antihypertensives
Pharmacologic Classification: ace inhibitors
Absorption: 37% absorbed after oral administration.
Distribution: Unknown.
Protein Binding: 95%.
Metabolism/Excretion: Converted by the liver to benazeprilat, the active metabolite; 20% excreted in urine; 11–12% nonrenal (biliary) elimination.
Half-Life: Benazeprilat: 10–11 hr.
(antihypertensive effect)
| ROUTE | ONSET | PEAK | DURATION |
|---|
| PO | within 1 hr* | 1–2 wk‡ | 24 hr‡ |
